Co-chaperone BAG2 Determines the Pro-oncogenic Role of Cathepsin B in Triple-Negative Breast Cancer Cells.

Triple-negative breast cancer (TNBC) is considered incurable with currently available treatments, highlighting the need for therapeutic targets and predictive biomarkers. Here, we report a unique role for Bcl-2-associated athanogene 2 (BAG2), which is significantly overexpressed in TNBC, in regulating the dual functions of cathepsin B as either a pro- or anti-oncogenic enzyme. Silencing BAG2 suppresses tumorigenesis and lung metastasis and induces apoptosis by increasing the intracellular mature form of cathepsin B, whereas BAG2 expression induces metastasis by blocking the auto-cleavage processing of pro-cathepsin B via interaction with the propeptide region. BAG2 regulates pro-cathepsin B/annexin II complex formation and facilitates the trafficking of pro-cathespin-B-containing TGN38-positive vesicles toward the cell periphery, leading to the secretion of pro-cathepsin B, which induces metastasis. Collectively, our results uncover BAG2 as a regulator of the oncogenic function of pro-cathepsin B and a potential diagnostic and therapeutic target that may reduce the burden of metastatic breast cancer.

[1]  C. Gondi,et al.  Cathepsin B as a cancer target , 2013, Expert opinion on therapeutic targets.

[2]  David S. Park,et al.  BAG2 Gene-mediated Regulation of PINK1 Protein Is Critical for Mitochondrial Translocation of PARKIN and Neuronal Survival* , 2015, The Journal of Biological Chemistry.

[3]  O. Vasiljeva,et al.  Reduced tumour cell proliferation and delayed development of high-grade mammary carcinomas in cathepsin B-deficient mice , 2008, Oncogene.

[4]  C. Borchers,et al.  Regulation of the Cytoplasmic Quality Control Protein Degradation Pathway by BAG2* , 2005, Journal of Biological Chemistry.

[5]  Bonnie F. Sloane,et al.  Human Procathepsin B Interacts with the Annexin II Tetramer on the Surface of Tumor Cells* , 2000, The Journal of Biological Chemistry.

[6]  Bonnie F. Sloane,et al.  Lysosomal cathepsin B participates in the podosome-mediated extracellular matrix degradation and invasion via secreted lysosomes in v-Src fibroblasts (Cancer Research (2008) 68, (9147-9156)) , 2009 .

[7]  C. Sotiriou,et al.  TP53 mutation‐correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53‐mutated breast cancers , 2014, Molecular oncology.

[8]  C. Peters,et al.  Transgenic expression of human cathepsin B promotes progression and metastasis of polyoma-middle-T-induced breast cancer in mice , 2011, Oncogene.

[9]  Xuesong Lu,et al.  Predicting features of breast cancer with gene expression patterns , 2008, Breast Cancer Research and Treatment.

[10]  M. Martino,et al.  Inhibition of cathepsin B by its propeptide: Use of overlapping peptides to identify a critical segment , 1996, FEBS letters.

[11]  P. Bonaldo,et al.  Annexin A2 mediates secretion of collagen VI, pulmonary elasticity and apoptosis of bronchial epithelial cells , 2014, Journal of Cell Science.

[12]  Lin Liu,et al.  Physical and functional interactions of SNAP-23 with annexin A2. , 2007, American journal of respiratory cell and molecular biology.

[13]  D. Hanahan,et al.  Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. , 2004, Cancer cell.

[14]  Funda Meric-Bernstam,et al.  Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes , 2013, Clinical Cancer Research.

[15]  Bonnie F. Sloane,et al.  Mutant K-ras regulates cathepsin B localization on the surface of human colorectal carcinoma cells. , 2003, Neoplasia.

[16]  W. Nastainczyk,et al.  BAG-2 acts as an inhibitor of the chaperone-associated ubiquitin ligase CHIP. , 2005, Molecular biology of the cell.

[17]  J. Foekens,et al.  miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs , 2013, Breast Cancer Research.

[18]  Bonnie F. Sloane,et al.  Lysosomal cathepsin B participates in the podosome-mediated extracellular matrix degradation and invasion via secreted lysosomes in v-Src fibroblasts. , 2008, Cancer research.

[19]  Wenwei Hu,et al.  BAG2 promotes tumorigenesis through enhancing mutant p53 protein levels and function , 2015, eLife.

[20]  Jorge S Reis-Filho,et al.  Triple-negative breast cancer. , 2010, The New England journal of medicine.

[21]  D. Turk,et al.  Crystal structure of the wild-type human procathepsin B at 2.5 A resolution reveals the native active site of a papain-like cysteine protease zymogen. , 1997, Journal of molecular biology.

[22]  V. Herzog,et al.  Trafficking of lysosomal cathepsin B—green fluorescent protein to the surface of thyroid epithelial cells involves the endosomal/lysosomal compartment , 2002, Journal of Cell Science.

[23]  A. C. Storer,et al.  Identification of Internal Autoproteolytic Cleavage Sites within the Prosegments of Recombinant Procathepsin B and Procathepsin S , 2001, The Journal of Biological Chemistry.

[24]  Bonnie F. Sloane,et al.  Cathepsin B inhibition limits bone metastasis in breast cancer. , 2012, Cancer research.

[25]  Bonnie F. Sloane,et al.  Cysteine cathepsins: multifunctional enzymes in cancer , 2006, Nature Reviews Cancer.

[26]  Bonnie F. Sloane,et al.  Human tumour cathepsin B. Comparison with normal liver cathepsin B. , 1992, The Biochemical journal.

[27]  X. Meng,et al.  Induction of BAG2 protein during proteasome inhibitor‐induced apoptosis in thyroid carcinoma cells , 2008, British journal of pharmacology.

[28]  C. Hudis,et al.  Triple-negative breast cancer: an unmet medical need. , 2011, The oncologist.

[29]  Bonnie F. Sloane,et al.  Cathepsin B: multiple enzyme forms from a single gene and their relation to cancer. , 1996, Enzyme & protein.

[30]  D. Dinh,et al.  Cathepsin B facilitates autophagy-mediated apoptosis in SPARC overexpressed primitive neuroectodermal tumor cells , 2010, Cell Death and Differentiation.

[31]  J. Crown,et al.  Emerging targeted therapies in triple-negative breast cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  T. Welte,et al.  Cathepsin-regulated apoptosis , 2006, Apoptosis.

[33]  Kenji Mizuguchi,et al.  Applying the Naïve Bayes classifier with kernel density estimation to the prediction of protein-protein interaction sites , 2010, Bioinform..

[34]  W. Gerald,et al.  Genes that mediate breast cancer metastasis to the brain , 2009, Nature.

[35]  Marcel Leist,et al.  Cathepsin B Acts as a Dominant Execution Protease in Tumor Cell Apoptosis Induced by Tumor Necrosis Factor , 2001, The Journal of cell biology.

[36]  J. Joyce,et al.  Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response , 2015, Nature Reviews Cancer.